When a Savings Card Stops Counting Toward Your Deductible

Answer first: the rule says may, not must

There is one sentence of federal regulation underneath this whole subject, and it is worth reading before anything else. Money paid on your behalf by a drug manufacturer may be, but is not required to be, counted toward your annual limitation on cost sharing.

That limitation is the out-of-pocket maximum — the ceiling that is supposed to stop your spending for the year. So the regulation is not silent on whether a card counts. It answers the question, and the answer is that your plan gets to decide.

Two people with the same drug, the same card, and the same pharmacy can therefore end the year in completely different positions. Nothing went wrong for either of them. They had different plans.

The practical consequence is blunt. A card can cut what you hand over at the counter to almost nothing while moving your deductible and your out-of-pocket total by almost nothing, and both things are true at once.

Where the rule actually is

It sits in the federal regulation on cost-sharing requirements for health insurance issuers, at paragraph (h), under the heading "Use of direct support offered by drug manufacturers."

The sentence has two halves. The first is a condition: to the extent consistent with State law.

The second is the rule itself. Amounts paid toward reducing an enrollee's cost sharing, using any form of direct support offered by drug manufacturers, may be counted toward the annual limitation on cost sharing.

May be, and are not required to be. That is the regulation's own phrasing, and everything here turns on it. The rule attaches it to specific prescription drugs.

Read the phrase "any form of direct support" carefully, because it is doing a lot of work. It is not limited to a plastic copay card. It reaches whatever shape the manufacturer's help arrives in.

Note the other qualifier too. "To the extent consistent with State law" means the federal rule yields where a state has legislated, which is why this ends up being a state-by-state question rather than a national one.

One more piece of precision is worth keeping. The regulation speaks about the annual limitation on cost sharing, which is the out-of-pocket maximum. The deductible is a separate running total, and in practice a plan that declines to credit manufacturer support usually declines on both.

What the industry calls it, in the government's own words

The agency that wrote the rule described the practice plainly when it finalized the current wording. It called these arrangements accumulator adjustment programs.

Its definition is short and it is the clearest one you will find anywhere. They are utilization management tools that pharmacy benefit managers and health plans may use, which exclude copay assistance from counting toward a patient's deductible or annual limitation on cost sharing.

Two things in that sentence deserve attention. The first is "utilization management tools" — the same family of words as prior authorization and step therapy, and a signal that this is a deliberate benefit design rather than an accounting quirk.

The second is who runs it. Pharmacy benefit managers sit between your plan and the pharmacy.

This is one of the places where a decision made there shows up in your life, without your plan ever writing to you about it.

The agency did not merely permit this. It encouraged it.

This is the part almost nobody knows, and it explains why the practice spread rather than stayed rare.

In finalizing the rule, the agency said issuers have flexibility, when consistent with state law, to determine if and how to factor in direct manufacturer support toward the annual limitation on cost sharing. It added that issuers and group health plans remain free to continue longstanding policies on how that support accrues, and that it was not directing anyone to any specific practice.

Then it went further. It said it encourages issuers and group health plans to consider the flexibility to exclude these amounts from the annual limitation on cost sharing, as one tool to address high and rising out-of-pocket drug costs.

The stated reasoning was about brand versus generic. The concern was a market distortion, in which manufacturer support steers a patient toward a higher-cost brand-name drug — over a generic the agency described as equally effective and medically appropriate.

Whatever you think of that reasoning, notice where it leaves someone taking a brand-name drug with no generic equivalent. The policy's logic was built around a substitution that may not be available to you at all, and the rule applies to you regardless.

The high-deductible plan wrinkle

If your plan is a high-deductible one paired with a health savings account, there is a second layer here, and it came up directly in the rulemaking.

Commenters raised the tax rules that define a high-deductible health plan, and asked whether counting manufacturer assistance toward the deductible could conflict with them. The agency's response was that its policy is intended to provide maximum flexibility and to let issuers avoid that kind of conflict where it arises.

Translated: the flexibility to not count your card is partly there so that plans can stay inside the tax definition. That is a structural reason rather than a discretionary one, and it makes the practice more likely on exactly the plans with the largest deductibles.

So if you chose a high-deductible plan expecting a card to help you clear that deductible faster, check the assumption before the year runs. It is the plan design where the assumption is least likely to hold.

How to tell whether it is happening to you

You will not usually be told. The card works, the pharmacy hands you the medication, and the amount simply never appears in the total your plan is tracking.

The check is a comparison, and it takes two documents. Take what the card paid on a fill, then look at what your plan reports for your deductible and out-of-pocket totals before and after that fill. If the card's contribution is missing from the movement, you have your answer.

Your explanation of benefits is where the plan's version of a fill is written down, and your plan's member portal usually shows the running totals. Neither is a bill, and reading them together is the only way to see this.

Then read your plan's pharmacy benefit documents for language about manufacturer assistance, copay assistance, or a variable copay program. The practice is generally disclosed somewhere in the plan documents even when it is never highlighted.

If the totals are not moving and you cannot find the language, call the number on your card. Ask the question in plain terms.

Does support from the manufacturer count toward my deductible and my out-of-pocket maximum? Ask for that answer in writing.

What to establish, in order

Start with whether you are using insurance at all. A card layered on top of a plan is the situation this rule governs. Paying cash outside your plan is a different question entirely, and money spent there generally earns no credit toward anything.

Then establish which state's law applies to your coverage, and whether your plan is one your state can regulate. The federal rule defers to state law, so that is where an answer that overrides the default would come from. Your state's insurance department is the place to ask.

Then get your plan's own position in writing, because that is the fact that actually governs your year.

Finally, do the arithmetic with the real numbers before you commit to a channel for the year. A card that makes a month look cheap and a deductible that never moves can be the more expensive path once your other medical costs are in the picture.